The biopharmaceutical company Pharnext was founded in April 2007 by Professor Daniel Cohen and his main collaborators. Pharnext's mission is to discover and develop new therapeutic solutions (PleodrugsTM) and companion tests for unmet medical needs by using the PleotherapyTM approach.

We are pleased to announce an additional €8 million round that takes the total raised in 2011 to €10.5 million. This rounds of funding are intended to finance the further Phase II clinical development of Pharnext's first PleodrugTM in Charcot-Marie-Tooth disease type 1A and the ongoing development in Alzheimer's disease.